Including contributions from leading experts at organizations such as the FDA, NIH, and PAREXEL, the Third Edition of this highly successful, jargon-free publication serves as a roadmap to prescription drug, biologics, and medical device development in the US.
Read More
Including contributions from leading experts at organizations such as the FDA, NIH, and PAREXEL, the Third Edition of this highly successful, jargon-free publication serves as a roadmap to prescription drug, biologics, and medical device development in the US.
Read Less